New Developments in the Treatment of Metastatic Breast Cancer
When breast cancer spreads to other organs, patients and their families face many questions. Treatment aims to control the disease for as long as possible, extend life and preserve everyday wellbeing. A growing range of options now allows care to be planned more closely around the tumour’s characteristics and the treatments already received. [1] Choosing treatment begins with understanding the disease again. When appropriate, a biopsy of a metastasis reassesses hormone receptors and HER2, which can change over time. Tumour tissue or a blood-based liquid biopsy may identify changes in ESR1, PIK3CA, AKT1 or PTEN. Testing for inherited BRCA1/2 changes can also guide options such as PARP inhibitors in eligible patients. Tests are chosen according to how their results could influence care. [2] For hormone receptor-positive, HER2-negative disease, endocrine therapy with a CDK4/6 inhibitor remains an important initial approach for many patients. When resistance develops, molecular findings may guide a change in endocrine treatment or the use of medicines targeting the PI3K/AKT pathway. A 2026 development is switching endocrine treatment to camizestrant while continuing the CDK4/6 inhibitor in selected patients when an ESR1 mutation appears in blood, before progression is seen on scans. Based on SERENA-6, this approach received accelerated US approval; it is not a routine strategy for everyone. [2,3,8] In HER2-positive disease, antibody–drug conjugates are changing treatment sequences. Trastuzumab deruxtecan with pertuzumab received US approval as an initial treatment after showing longer control without disease progression. This drug class combines a targeted antibody with chemotherapy. Close monitoring remains necessary, including for inflammation of the lungs. [4] Tumours with low or ultralow HER2 expression can now be assessed for an additional treatment option. Eligible patients with hormone receptor-positive metastatic disease that has progressed after endocrine therapy may benefit from trastuzumab deruxtecan when their tumour is HER2-low or HER2-ultralow. Accurately assessing the detail in the HER2 pathology result therefore matters. [5] First-line options for metastatic triple-negative breast cancer also expanded in 2026. Sacituzumab govitecan received US approval with pembrolizumab for patients meeting the PD-L1 threshold, or alone for those unsuitable for PD-1/PD-L1 treatment. Another antibody–drug conjugate, datopotamab deruxtecan, became an option for patients unsuitable for PD-1/PD-L1 therapy. Previous treatments and the patient’s health help determine which option is appropriate. [6,7] Having a new medicine matters, but so does using it at the right time for the right person. Its likely benefits, side effects and availability in Türkiye should be discussed openly. Pain relief, nutrition, psychological support and the patient’s own priorities remain essential parts of care. Sources [1] NCI · Breast cancer | [2] ESMO · 2026 | [3] Camizestrant · FDA 2026 | [4] HER2 positive · FDA | [5] HER2 low · FDA | [6] Sacituzumab · FDA 2026 | [7] Datopotamab · FDA 2026 | [8] SERENA-6 · NEJM
Treatment selection begins with re-diagnosing the disease. When appropriate, a biopsy is taken from the metastatic site to re-evaluate hormone receptors and HER2; these characteristics can change over time. If necessary, changes such as ESR1, PIK3CA, AKT1 and PTEN are investigated in the tumor tissue or in liquid blood biopsy. Hereditary BRCA1/2 investigation can also guide options such as PARP inhibitors in suitable patients. Each test is selected considering the contribution of its result to treatment. [2]
In hormone receptor-positive, HER2-negative disease, hormone therapy and CDK4/6 inhibitors remain an important initial approach for many patients. When resistance develops, it is possible to change hormone therapy based on molecular results or to utilize drugs targeting the PI3K/AKT pathway. One of the innovations in 2026 is the switching of hormone therapy to kamisetran and the continuation of CDK4/6 inhibitor without waiting for imaging progression when an ESR1 mutation is detected in the blood of certain patients. This approach, based on SERENA-6 data, received accelerated approval in the US; however, it does not mean routine application in every patient. [2,3,8]
In HER2-positive disease, antibody-mediated chemotherapies are changing the treatment sequence. The first-line use of trastuzumab deruxtecan in combination with pertuzumab has been approved in the US following results that prolong the time the disease remains under control without progression. This group of drugs combines targeted antibody chemotherapy; close monitoring for side effects, including pneumonia, is required during treatment. [4]
Tumors with low or very low HER2 levels are now also being evaluated as a separate treatment option. In hormone receptor-positive metastatic disease, when progression occurs after hormone therapy, suitable patients with low or very low HER2 levels can benefit from trastuzumab deruxtecan. Therefore, accurate evaluation of the HER2 detail in the pathology report is important. [5]
First-line options for triple-negative metastatic breast cancer also expanded in 2026. Sacituzumab govitecan was approved in the US in combination with pembrolizumab in patients with appropriate PD-L1 levels, and alone in those unsuitable for PD-1/PD-L1 treatment. Datopotamab deruxtecan, in the same group, also became a new option for patients unsuitable for PD-1/PD-L1 treatment. Which drug to choose is determined by evaluating previous treatments and the individual's condition together. [6,7]
Just as important as discovering a new drug is using it at the right time and for the right person. The expected benefits of the treatment, its side effects, and accessibility in Türkiye should be openly discussed. Pain management, nutrition, psychological support, and the patient's own priorities should also be addressed as integral parts of the treatment.
Sources [1] NCI · Breast cancer | [2] ESMO · 2026 | [3] Camizestranger · FDA 2026 | [4] HER2 positive · FDA | [5] HER2 low · FDA | [6] Sacituzumab · FDA 2026 | [7] Datopotamab · FDA 2026 | [8] SERENA-6 · NEJM
